Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 19;150(2):96.
doi: 10.1007/s00432-024-05623-7.

Current look at the most promising proteomic and glycomic biomarkers of bladder cancer

Stefan Harsanyi  1 , Kristina Kianickova  2 , Jaroslav Katrlik  2 , Lubos Danisovic  3 , Stanislav Ziaran  4
Affiliations
Review

Current look at the most promising proteomic and glycomic biomarkers of bladder cancer

Stefan Harsanyi et al. J Cancer Res Clin Oncol. .

Abstract

Background: Bladder cancer (BC) belongs to the most frequent cancer types. The diagnostic process is still long and costly, with a high percentage of false-positive or -negative results. Due to the cost and lack of effectiveness, older methods need to be supplemented or replaced by a newer more reliable method. In this regard, proteins and glycoproteins pose high potential.

Methods: We performed an online search in PubMed/Medline, Scopus, and Web of Science databases to find relevant studies published in English up until May 2023. If applicable, we set the AUC threshold to 0.90 and sensitivity/specificity (SN/SP) to 90%.

Findings: Protein and glycoprotein biomarkers are a demonstrably viable option in BC diagnostics. Cholinesterase shows promise in progression-free survival. BLCA-4, ORM-1 along with HTRA1 in the detection of BC. Matrix metallopeptidase 9 exhibits potential for stratification of muscle-invasive subtypes with high negative predictive value for aggressive phenotypes. Distinguishing non-muscle invasive subtypes benefits from Keratin 17. Neu5Gc-modified UMOD glycoproteins pose potential in BC diagnosis, while fibronectin, laminin-5, collagen type IV, and lamprey immunity protein in early detection of BC.

Keywords: Biomarkers; Bladder cancer; Diagnostics; Glycoprotein; Protein.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflicts of interest concerning the research, authorship, and/or publication of this article.

Figures

Fig. 1
Fig. 1
Association of proteomic and glycomic markers with BC diagnosis
See this image and copyright information in PMC

References

    1. Adamia S, Maxwell CA, Pilarski LM (2005) Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord 5:3–14. 10.2174/1568006053005056 - PubMed
    1. Al Khader A, Fararjeh AFS, Kaddumi EG, Al-Saghbini M (2022) Significance of fibulin-3 expression in bladder cancer: a tissue microarray-based immunohistochemical study. World J Surg Oncol 20:133. 10.1186/s12957-022-02597-z - PMC - PubMed
    1. Alavi A, Izadpanahi M-H, Haghshenas L, Faridizad R, Eslami M-J, Ghadimi K (2019) Comparing urine levels of BLCA-4 nuclear matrix protein in patients with bladder cancer and non-bladder cancer. Int J Physiol Pathophysiol Pharmacol 11:289–292 - PMC - PubMed
    1. Altobelli E, Angeletti PM, Morroni M, Profeta VF (2018) HtrA1 as a promising tissue marker in cancer: a meta-analysis. BMC Cancer 18:143. 10.1186/s12885-018-4041-2 - PMC - PubMed
    1. Amano N, Matsumoto K, Shimizu Y, Nakamura M, Tsumura H, Ishii D et al (2021) High HNRNPA3 expression is associated with lymph node metastasis and poor prognosis in patients treated with radical cystectomy. Urol Oncol 39:196.e1-196.e7. 10.1016/j.urolonc.2020.10.072 - PubMed